Transjugular Intrahepatic Portosystemic Shunting as a therapeutic option in Hepatorenal Syndrome - promising results from a nationwide cohort.
AASLD LiverLearning®, Paris Charilaou, 195328
Hepalatide Ameliorated Progression of Mouse Nonalcoholic Steatohepatitis Caused by Feeding High Fat/Calorie Diet plus High Fructose and Glucose in Drinking Water
AASLD LiverLearning®, Xue-Jing Liu, 195584
Outcomes of TIPS for Ascites as a Function of Baseline Renal Function
AASLD LiverLearning®, Ranya Selim, 195329
Dicosylhexaenoic Acid Reversed Progression of NASH to Hepatic Fibrosis in Mice by Increasing Ratio of ω-3 over ω-6 Fatty Acids
AASLD LiverLearning®, Xue-Jing Liu, 195585
Comparison of MELD-Na and MELD scores in predicting survival following transjugular intrahepatic portosystemic shunt in patients with cirrhosis
AASLD LiverLearning®, Carrie Hamilton, 195330
Transjugular Intrahepatic Portosystemic Shunt Prior to Abdominal Surgery: Outcomes in Cirrhotics
AASLD LiverLearning®, Mohamed Shoreibah, 195343
Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism
AASLD LiverLearning®, Hirokazu Takahashi, 195599
Efficacy and safety of tolvaptan in the treatment of patients with decompensated liver cirrhosis and severe chronic kidney disease
AASLD LiverLearning®, Yoshitaka Arase, 195344
Insulin signaling as a potential NK cell checkpoint in Fatty Liver Disease
AASLD LiverLearning®, Johnny Amer, 195600
Transjugular intrahepatic portosystemic shunt (TIPS): a safe and efficacious treatment strategy for cirrhotic patient with splanchnic vein thrombosis
AASLD LiverLearning®, Stella De Nicola, 195345
Bile Acid and Steroid Transporter OSTα/β is Over-Expressed in Liver from Patients With Non-alcoholic Steatohepatitis (NASH) and Primary Biliary Cirrhosis (PBC), and Modulated by Drugs Using a Novel In Vitro Cell System
AASLD LiverLearning®, Melina Malinen, 195601
Sequential CLIF-SOFA (C-S) scores decrease with terlipressin therapy and correlate more strongly with survival than baseline scores, in subjects with acute-on-chronic-liver failure (ACLF) and hepatorenal syndrome Type 1 (HRS-1)
AASLD LiverLearning®, Florence Wong, 195346
Development of Hepatocellular Carcinoma (HCC) in Fibroblast Growth Factor 21 (FGF21) Deficient Mice With Chronic Consumption of Obesogenic Diet
AASLD LiverLearning®, Garima Singhal, 195359
Aging exacerbates high-fat diet-induced steatohepatitis through blunting of lipid metabolic response in mice
AASLD LiverLearning®, Kei Ishizuka, 195615
PLOD2 induced under hypoxia is involved in resistance to gemcitabine and poor prognosis in biliary tract cancer
AASLD LiverLearning®, Yuichiro Okumura, 195360
Semaglutide, a novel long acting GLP-1 receptor agonist, reduced features of NASH in two different diet-induced mouse models
AASLD LiverLearning®, Jenny Norlin, 195616
Targeting CD44v9-xCT system by sulfasalazine to overcome cisplatin resistance in human liver cancer cells
AASLD LiverLearning®, Fumitaka Wada, 195361
IL-33/Cyclin D1 Imbalance in Severe Liver Steatosis Predicts Susceptibility to Ischemia Reperfusion Injury in Rats.
AASLD LiverLearning®, Kelley Nunez, 195617
Src Family Kinases regulates YAP nuclear localization and activity via tyrosine phosphorylation in cholangiocarcinoma.
AASLD LiverLearning®, Takaaki Sugihara, 195362
Lipid metabolism regulates oncogenic FoxM1 transcription factor in human hepatocellular carcinoma via the mevalonate-Rho pathway
AASLD LiverLearning®, Yuichi Yoshida, 195375
Consumption of decaffeinated coffee protects mice from the development of early non-alcoholic steatohepatitis: Role of intestinal barrier function
AASLD LiverLearning®, Annette Brandt, 195631
Specific ZnPP inhibition and degradation of telomerase in human hepatoma cells
AASLD LiverLearning®, Warren Schmidt, 195376
Oral digoxin inhibits liver injury to a comparable degree to obeticholic acid in a high fat model of NASH
AASLD LiverLearning®, Wajahat Mehal, 195632
TAP-1 Mediates Drug Resistance in Hepatoma Cells through Activation of Hedgehog Signaling
AASLD LiverLearning®, Xiaotian Zhou, 195377
Fructose-Related Hepatic ATP Depletion Induces Hyperuricemia in Healthy Volunteers and Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.
AASLD LiverLearning®, Manal Abdelmalek, 195633
The protein kinase CK2 contributes to the protumorigenic properties of cholangiocarcinoma cells
AASLD LiverLearning®, Fabio Marra, 195378
Growth Differentiation Factor 11 restricts HCC clonal expansion by disrupting glycolysis and decreasing lipid accumulation
AASLD LiverLearning®, Concepcion Gutierrez Ruiz, 195391
The prevalence of liver stiffness and hepatic steatosis as measured by vibration-controlled transient elastography in a community-based cohort: The Framingham Heart Study.
AASLD LiverLearning®, Michelle Long, 195647
Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model
AASLD LiverLearning®, Dong Hyeon Lee, 195392
A Quantitative Imaging Biomarker Assessment Metric for MRI-estimated Proton Density Fat Fraction
AASLD LiverLearning®, Michael Middleton, 195648
Inhibition of systemic hyaluronan synthesis exacerbates murine hepatic carcinogenesis
AASLD LiverLearning®, Kenichiro Mikami, 195393
Assessing the severity of liver fibrosis and steatosis in biopsy-proven NAFLD patients using MR imaging, transient elastography and serum biomarker
AASLD LiverLearning®, Young-Sun Lee, 195649
Genome-wide methylation analysis identified a new intrahepatic angiogenesis marker associated with induction of tumorigenesis after successful eradication of HCV
AASLD LiverLearning®, Masashi Nishikawa, 195394
Antibody and Cell-mediated Immunity against PreS1, PreS2 and S Antigens after Immunization with a Third Generation Hepatitis B Vaccine
AASLD LiverLearning®, Francisco Diaz-Mitoma, 195407
Role of common prosteatotic gene variants in primary sclerosing cholangitis
AASLD LiverLearning®, Marcin Krawczyk, 195663
Hepatitis B core-related antigen (HBcrAg) is useful marker in HBV/HDV co-infection and can help to predict response to pegylated interferon therapy
AASLD LiverLearning®, Ivana Carey, 195408
High-throughput RNA sequencing on liver biopsy material stratifies patients with non-alcoholic fatty liver disease
AASLD LiverLearning®, Olivier Govaere, 195664
A Pilot Program Integrating Hepatitis B Virus (HBV) Screening Into An Outpatient Endoscopy Unit Improves HBV Screening from 24.5% to 75.6% Among An Ethnically Diverse Safety-Net Public Hospital
AASLD LiverLearning®, Robert Wong, 195409
Prediction of advanced fibrosis in morbidly obese patients with nonalcoholic fatty liver disease
AASLD LiverLearning®, Tavankit Singh, 195665
Prevalence of Hepatitis B Serological Markers and Receipt of Hepatitis B Vaccine among a Cohort of Hepatitis C Infected Patients in a Large, Urban Health System, 2004--2016
AASLD LiverLearning®, Aaron Harris, 195410
Durability of Spontaneous- And Treatment-Related HBsAg Loss
AASLD LiverLearning®, Ahmad Alawad, 195423
Nonalcoholic fatty liver disease is associated with impaired bone strength in men with abdominal obesity
AASLD LiverLearning®, Tracey Simon, 195679
Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 35 year Follow-up Study and Response to a Booster Dose
AASLD LiverLearning®, Michael Bruce, 195424
Rising Healthcare Costs and Comorbidities Among Nonalcoholic Steatohepatitis (NASH) Patients with Advanced Fibrosis and Cirrhosis: A Longitudinal Real-World Analysis of US Patients
AASLD LiverLearning®, Rohit Loomba, 195680
Genetic characteristics and evolution of pre-S/S genes in the occult hepatitis B virus infection.
AASLD LiverLearning®, ChiehJu Lee, 195425
NGM282 Induces Low Density Lipoprotein Cholesterol (LDLc) Changes, Consistent with Potent FGFR4 Signaling, which are Rapidly Mitigated with Statin Therapy in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Mary Rinella, 195681
Use of various complementary and alternative medicine practices in an ethnically diverse chronic hepatitis B population: role of ethnicity and acculturation
AASLD LiverLearning®, Kin Seng Liem, 195426
Development and Validation of a Risk Score for Hepatocellular Carcinoma in Chronic Hepatitis B Patients under Antiviral Treatment
AASLD LiverLearning®, Yao-Chun Hsu, 195439
Increased risk of venous thromboembolism in patients with cirrhosis due to non-alcoholic steatohepatitis
AASLD LiverLearning®, Blake Niccum, 195695
Do HBsAg concentrations > 4 log10IU/ml represent a risk for mother to child transmission of HBV infection in all chronic hepatitis B patients?
AASLD LiverLearning®, Ivana Carey, 195440
Validity of Noninvasive Scores to Detect Nonalcoholic Fatty Liver Disease and its Advanced Form in Patients with Type 2 Diabetes.
AASLD LiverLearning®, Amandeep Singh, 195696
Web-based education program improves patient education and understanding of chronic Hepatitis B
AASLD LiverLearning®, Enoka Gonsalkorala, 195441
Search for Rare Mutations in Metabolic Pathways Associated with Nonalcoholic Fatty Liver Disease: The role of Glucokinase regulator (GCKR) Sequence Variation
AASLD LiverLearning®, Silvia Sookoian, 195697
Reactivation of Hepatitis B in Patients With Isolated Hepatitis B core Antibody Who Received Chemotherapy: Meta-analysis
AASLD LiverLearning®, Niharika Samala, 195442
Performance of an automated prototype assay for the detection and quantification of Hepatitis B pregenomic RNA in chronic HBV patients receiving nucleo(t)side analogue therapy
AASLD LiverLearning®, Emily Butler, 195455
Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH
AASLD LiverLearning®, A. Sidney Barritt, 195711
Evaluation of in vitro diagnostic kits for detection and quantification of HBV DNA and HBsAg using HBV reference panel
AASLD LiverLearning®, Asako Murayama, 195456
Preliminary evidence of an association between mtDNA D-loop polymorphisms and the clinicopathological features of nonalcoholic steatohepatitis
AASLD LiverLearning®, Yusuf Yilmaz, 195712
Hepatitis B virus replication enhances promoter activity of alpha-fetoprotein in human liver cell line
AASLD LiverLearning®, Jae hee Choi, 195457
Impact of a Structured Exercise, Nutrition and Patient Education Program on Short Term Outcomes in Patients with Non-Alcoholic Fatty Liver Disease
AASLD LiverLearning®, Monica Konerman, 195713
Hepatitis B virus (HBV) reactivation in patients treated with Ibrutinib for hematologic malignancies
AASLD LiverLearning®, Sarah Hammond, 195458
Passive Transfer of Hepatitis B Core Antibody after Intravenous Immunoglobulin Administration in Patients Receiving Anti-cancer Therapy
AASLD LiverLearning®, Jessica Hwang, 195471
A prospective evaluation of noninvasive modalities of liver fibrosis assessment in biopsy-proven nonalcoholic fatty liver disease
AASLD LiverLearning®, Alessandro Furlan, 195727
Prospective Assessment Of Frequency And Factors Associated With Bone Loss During Tenofovir Therapy In Patients With Chronic Hepatitis B
AASLD LiverLearning®, Ahmad Alawad, 195472
Natural course of chronic hepatitis B virus infection in children: A retrospective real-world data analysis
AASLD LiverLearning®, Xiaoben Pan, 195473
The Relationship Between NAFLD and the Risk of Obstructive Sleep Apnea
AASLD LiverLearning®, Chan Ran You, 195730
Noninvasive methods predict long term overall survival and specific complications in non-alcoholic fatty liver disease
AASLD LiverLearning®, Sarah Shili, 195731
Increase of serum chylomicron triglyceride concentration associated with intestinal overproduction of chylomicron triglyceride in nonobese, nondiabetic and normolipidemic NASH patients
AASLD LiverLearning®, Hiroki Utsunomiya, 195732
L-leucine supplementation reverses hyperammonemia induced skeletal muscle mitochondrial dysfunction
AASLD LiverLearning®, Allawy Allawy, 195487
Cirrhosis resolution dose not resolve all derangements of portal hypertension
AASLD LiverLearning®, Shao-Jung Hsu, 195488
Left Atrial Dynamics assessed with Real Time 3-Dimensional Echocardiography in relation to Liver Function in Cirrhosis
AASLD LiverLearning®, Silje Mo, 195489
The Association of Nonalcoholic Steatohepatitis and Obstructive Sleep Apnea
AASLD LiverLearning®, Mohammad Maysara Asfari, 195746
IRGM gene variants modify the relationship between visceral adipose tissue and NAFLD in patients with Crohn’s Disease
AASLD LiverLearning®, Tracey Simon, 195747
Characteristics and Costs of NASH Advanced Fibrosis and Cirrhosis in Patients with and without Diabetes Mellitus (DM): Results of a US Real-World Cohort Study
AASLD LiverLearning®, Arun Sanyal, 195748
Modeling NAFLD Using 3D Bioprinted Human Liver Tissue
AASLD LiverLearning®, Alice Chen, 195503
Adipose tissue derived stromal/stem cells retarded progression of hepatic fibrosis by suppressing IL17A related inflammation in early stage of NASH.
AASLD LiverLearning®, Masatoshi Yamato, 195504
Role of Intestine-Specific Sirt1 in the Protective Action of Salvianolic Acid B against Ethanol-Induced Inflammation and Liver Injury in Mice
AASLD LiverLearning®, Hong Shen, 195505
Safety and Tolerability of the Dual CCR2/5 Antagonist Cenicriviroc in Over 1000 Participants Treated to Date
AASLD LiverLearning®, Manal Abdelmalek, 195762
The Global Epidemiology of Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
AASLD LiverLearning®, Zobair Younossi, 195763
Evaluation of kidney function in patients with Non-Alcoholic Fatty Liver Disease: The role of galectin-3
AASLD LiverLearning®, Emmanouil Sinakos, 195764
Pharmacological inhibition of RGD-binding integrins reverses liver fibrosis in a diet-based mouse model of nonalcoholic steatohepatitis
AASLD LiverLearning®, Hidenao Noritake, 195519
Efficacy of MET409, a potent, novel non-bile acid FXR agonist, in rodents and cynomolgus monkeys
AASLD LiverLearning®, Brandee Wagner, 195520
Early Anti-steatotic Actions of an Ileal Apical Sodium-dependent Bile Acid Transporter Inhibitor in High Fat Diet Fed Mice
AASLD LiverLearning®, Anuradha Rao, 195521
A Novel Retinol Dehydrogenase, HSD17B13 Contributes to the Pathogenesis of Non-Alcoholic Fatty Liver Disease
AASLD LiverLearning®, Yanling Ma, 195535
Somatotropic Axis Dysfunction In Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic And Systemic Effects Of Hormone Supplementation
AASLD LiverLearning®, Francisco Barrera, 195536
Loss of iron upregulates mitochondria ferritin and triggers mitophagy
AASLD LiverLearning®, Yuichi Hara, 195537
Metabolic and hepatic effects of clinical candidates liraglutide, elafibranor and obeticholic acid in obese mouse models with diet-induced and biopsy-confirmed NASH
AASLD LiverLearning®, Michael Feigh, 195551
Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2-/- mouse model of primary sclerosing cholangitis (PSC).
AASLD LiverLearning®, Tianhao Zhou, 195296
Fully human in vitro gut-liver model of non-alcoholic steatohepatitis
AASLD LiverLearning®, Tomasz Kostrzewski, 195552
Apical Sodium-Dependent Bile Acid Transporter Inhibition with Volixibat Impacts Metabolic and Physiologic Parameters Associated with the Development of Nonalcoholic Steatohepatitis (NASH) in a High-Fat Diet-Fed Mouse Model
AASLD LiverLearning®, Melissa Palmer, 195553
The microRNA-200c Is a Critical Novel Regulator of Cholestatic Liver Fibrosis
AASLD LiverLearning®, Yongfeng Song, 195298
Cholecystectomy increases secondary bile acids in the liver and results in liver injury in male but not female mice
AASLD LiverLearning®, Dongke Yu, 195311
Activation and Increased IFNγ Secretion of Invariant Natural Killer T Cells in a Human in-vitro Model of Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Jens Werner, 195567
NK cells in the ascites of patients with advanced liver cirrhosis are phenotypically distinct from blood and liver NK cells and may be involved in antibacterial defense
AASLD LiverLearning®, Philipp Lutz, 195312
The role of nitric oxide-mediated mechanisms in the increased intrahepatic vascular resistance in a rat model of non-alcoholic fatty liver disease
AASLD LiverLearning®, Denise van der Graaff, 195568
Rising Trend and Poor Waitlist Outcomes in Young Adult Liver Transplant Registrants with Alcoholic Liver Disease
AASLD LiverLearning®, George Cholankeril, 195313
Chemokine receptor 9 plays a crucial role in obesity-induced liver injury and glucose tolerance by modulating ectopic fat distribution with macrophage recruitment
AASLD LiverLearning®, Takeru Amiya, 195569
Performance of the calprotectin assay in ascitic fluid using the Quantum Blue® Reader for the diagnosis of spontaneous bacterial peritonitis in cirrhotic patients (The CADRISLA Study)
AASLD LiverLearning®, Delphine Weil, 195314
Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in hospitalized patients with decompensated cirrhosis
AASLD LiverLearning®, Adelina Hung, 195327
Oleate- but not palmitate-enriched diets induce iNKT cell activation in adipose tissue, resulting in hepatic steatosis
AASLD LiverLearning®, Amin Amin, 195583